Date: 2017-09-11
Type of information: Series B financing round
Company: Amphivena Therapeutics (USA - CA)
Investors: Tekla Capital Management (USA - MA)
Amount:
Funding type: series B financing round
Planned used:
- Amphivena plans to launch a Phase 1 clinical study in patients with MDS in early 2018. The company is also exploring the utility of AMV564 in solid tumors. In preclinical studies, this novel CD33/CD3 bispecificantibody demonstrated potent activity against AML patient samples that was independent of CD33 expression level, disease stage and cytogenetic risk. The antibody eliminated nearly all blasts from bone marrow and spleen in a stringent AML patient-derived xenograft murine model. In addition, Amphivena established a therapeutic window for AMV564 in cynomologus monkeys, with rapid, sustainedelimination of CD33-expressing cells during AMV564 dosing and rapid hematopoietic recovery following dosing.
Others:
- • On September 11, 2017, Amphivena Therapeutics, a privately held biotechnology company developing a novel CD33/CD3-bispecific T cell engaging antibody for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), announced that funds managed by Tekla Capital Management invested in Amphivena’s Series B Financing completed in July. Christian M. Richard, M.S., M.B.A., Senior Vice President, Research, joined Amphivena’s Board of Directors.
Therapeutic area: Cancer - Oncology - Rare diseases
Is general: Yes
